Akron Patient Managed Phenylketonuria With New Medication
In September 2025, a 14-year-old student became the first patient at Akron Children's Hospital to use Sephience.
Updated on Sept. 22, 2026 in Allergies
Eli Widmer, a student from Wadsworth, began treatment with the FDA-approved drug Sephience in September 2025 to manage his phenylketonuria. The medication helped lower his blood phenylalanine levels, allowing him to increase his protein intake.
Why it matters
The treatment addresses a condition that, if left untreated, can lead to serious health consequences such as brain damage and anxiety. By assisting the body in utilizing natural enzyme co-factors, the drug offers a path to fewer dietary restrictions.
Sephience carries an estimated annual cost of $492,000 per patient. Approximately 60% to 70% of metabolic patients at Akron Children's Hospital are diagnosed with phenylketonuria.
The players
Eli Widmer
He is a 14-year-old student who was the first patient at his local hospital to utilize the newly approved medication.
Akron Children's Hospital
It is a pediatric healthcare center that serves as the site for metabolic patient care and manages dozens of individuals on the new drug.
The details
Eli Widmer was the first patient at the hospital to start the regimen, which resulted in him adding 5 grams of protein to his diet on a weekly basis. The medication received FDA approval in July 2025 to help those struggling with strict protein intake limitations.
Timeline
July 2025: Sephience received FDA approval.
September 2025: Eli Widmer started taking Sephience.
September 22, 2026: Article publication date.
The Big Picture
The adoption of this therapy at the Akron Children's metabolic patient management program marks a transition toward using pharmaceutical intervention to supplement traditional dietary management. This shift reflects a move away from purely restrictive diets for metabolic patients.
The availability of this medication allows patients to expand their dietary protein intake, moving away from previously restrictive 6-gram daily limits. Families should consult with pediatric specialists regarding eligibility and the financial implications of high-cost specialty drugs.
The takeaway
Advancements in enzyme-supporting medication provide new options for managing metabolic conditions that were once treated solely through dietary restriction. Patients and families are encouraged to monitor blood level improvements to safely track the impact of new medical interventions.
Further reading
For additional context on managing sensitivities and dietary conditions, visit the Allergies section.
Source note: This article includes information reported by Akron Beacon Journal.
